The Anthrax drugs in development market research report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anthrax. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anthrax and features dormant and discontinued products.
GlobalData tracks 22 drugs in development for Anthrax by 20 companies/universities/institutes. The top development phase for Anthrax is preclinical with 14 drugs in that stage. The Anthrax pipeline has 15 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Anthrax pipeline products market are: Aphios, iBio and National Institute of Allergy and Infectious Diseases.
The key targets in the Anthrax pipeline products market include Anthrax Protective Antigen, Bacillus anthracis Lethal Factor, and Bacterial Cell Wall.
The key mechanisms of action in the Anthrax pipeline product include Anthrax Protective Antigen Inhibitor with two drugs in Preclinical. The Anthrax pipeline products include seven routes of administration with the top ROA being Intravenous and nine key molecule types in the Anthrax pipeline products market including Small Molecule, and Subunit Vaccine.
Anthrax overview
Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe bloody diarrhea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors include illegal intravenous drug use, exposure to animal skins, and working in veterinary medicine, especially dealing with livestock.
For a complete picture of Anthrax’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
